MONDAY, April 3, 2023 (HealthDay News) — An experimental targeted drug could provide a fresh chance for people with recurring head and neck cancer that has grown resistant to other treatments, a new clinical trial says. Ficlatuzumab used in combination with the already approved targeted drug cetuximab (Erbitux) significantly improvedContinue Reading

MONDAY, March 20, 2023 (HealthDay News) — In more bad news about antibiotic resistance, new research suggests that people and their pets may be able to transmit multidrug-resistant germs to each other. Still, cases of cross-transmission are rare and it’s not clear if pets are giving germs to people orContinue Reading